5 Methoxy N,N Dimethyltryptamine
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment Resistant Depression
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Depression
Trial Timeline
Nov 12, 2019 → Nov 6, 2021
NCT ID
NCT04698603About 5 Methoxy N,N Dimethyltryptamine
5 Methoxy N,N Dimethyltryptamine is a phase 1/2 stage product being developed by GH Research for Treatment Resistant Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT04698603. Target conditions include Treatment Resistant Depression, Major Depressive Disorder, Depression.
What happened to similar drugs?
3 of 20 similar drugs in Treatment Resistant Depression were approved
Approved (3) Terminated (3) Active (14)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
🔄Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
🔄Irinotecan liposome、5-Fluorouracil、Leucovorin + Placebo、5-Fluorouracil、LeucovorinJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06511947 | Phase 1 | Recruiting |
| NCT04698603 | Phase 1/2 | Completed |
| NCT04640831 | Phase 1 | Completed |
Competing Products
20 competing products in Treatment Resistant Depression